FibroGen Inc (NAS:FGEN)
$ 0.58 0.001 (0.17%) Market Cap: 58.45 Mil Enterprise Value: 48.65 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 49/100

FibroGen Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 07:00PM GMT
Release Date Price: $25.15 (+2.40%)
Kyuwon Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Okay. Welcome back, everyone, and thank you for joining us on Day 3 of the 42nd Annual Goldman Sachs Global Healthcare Conference. I'm Paul Choi, and I cover the mid-cap biotechnology sector here at the firm. And our next session will be with FibroGen.

Joining us from management is CEO, Enrique Conterno. What we'll do as in prior sessions is we'll turn it over to Enrique for some opening commentary, and then we'll go into Q&A. (Operator Instructions)

But otherwise, with that, we'll turn it over to Enrique.

Enrique A. Conterno
FibroGen, Inc. - CEO & Director

Thank you, Paul, and thank you for the invitation. A few comments on FibroGen. We are, of course, excited about the -- having the AdCom with the -- here in the U.S., and the preparations are going well. The AdCom is July 15. Also waiting for the regulatory decision in Europe. That's another important milestone for us.

And of course, I think, continue to be very bullish about our performance in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot